CLOSEClose Corporate Counsel Menu

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Elizabeth Cabraser, Lieff, Cabraser, Heimann & Bernstein. Photo: Jason Doiy/ALM

One of the more controversial and critical parts of Bayer’s $10 billion-plus settlements of Roundup cases last week is a separate deal to resolve future claims that—because it comes in a class action—faces judicial scrutiny and potential objections that may unravel the agreement.

Amanda Bronstad

Amanda Bronstad is the ALM staff reporter covering class actions and mass torts nationwide. She writes the email dispatch Critical Mass. She is based in Los Angeles.

More from this author


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.